Corient Private Wealth LLC Has $4.80 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Corient Private Wealth LLC lessened its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 8.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 121,245 shares of the biotechnology company's stock after selling 11,545 shares during the period. Corient Private Wealth LLC owned about 0.16% of Veracyte worth $4,801,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Jones Financial Companies Lllp grew its holdings in shares of Veracyte by 49.7% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 237 shares during the last quarter. US Bancorp DE grew its holdings in Veracyte by 57.4% during the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after acquiring an additional 647 shares during the last quarter. Principal Securities Inc. grew its holdings in Veracyte by 34.1% during the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock worth $76,000 after acquiring an additional 485 shares during the last quarter. KBC Group NV increased its position in Veracyte by 13.7% in the 3rd quarter. KBC Group NV now owns 2,677 shares of the biotechnology company's stock valued at $91,000 after acquiring an additional 323 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of Veracyte in the fourth quarter worth about $91,000.

Analysts Set New Price Targets

Several analysts have recently commented on VCYT shares. UBS Group increased their price target on shares of Veracyte from $46.00 to $49.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Craig Hallum began coverage on Veracyte in a report on Thursday, March 20th. They set a "buy" rating and a $45.00 price objective for the company. Stephens restated an "overweight" rating and issued a $45.00 price objective on shares of Veracyte in a report on Wednesday. Guggenheim reaffirmed a "buy" rating and set a $45.00 target price on shares of Veracyte in a report on Tuesday, February 25th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $37.00 target price (down previously from $38.00) on shares of Veracyte in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to MarketBeat, Veracyte has a consensus rating of "Moderate Buy" and an average target price of $43.40.

Remove Ads

Veracyte Stock Down 7.8 %

Veracyte stock traded down $2.64 during mid-day trading on Wednesday, hitting $31.05. 1,235,084 shares of the company's stock were exchanged, compared to its average volume of 811,078. The company's 50 day simple moving average is $38.19 and its 200-day simple moving average is $37.78. The firm has a market capitalization of $2.42 billion, a P/E ratio of -207.00 and a beta of 1.80. Veracyte, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $47.32.

Veracyte (NASDAQ:VCYT - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The company had revenue of $118.63 million for the quarter, compared to analyst estimates of $110.73 million. During the same quarter last year, the firm posted ($0.39) earnings per share. Research analysts expect that Veracyte, Inc. will post 0.68 EPS for the current year.

Insider Buying and Selling at Veracyte

In related news, Director Karin Eastham sold 10,000 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $40.30, for a total transaction of $403,000.00. Following the sale, the director now directly owns 18,497 shares in the company, valued at $745,429.10. This trade represents a 35.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company's stock.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.